Skip to main content
Top

Dermatology and Therapy

Issue 8/2024

Content (22 Articles)

Biomarkers in Cutaneous Keratinocyte Carcinomas

Erica Montano, Neal Bhatia, Jelena Ostojić

Treatment of Epidermolysis Bullosa and Future Directions: A Review

Sorina Danescu, Mircea Negrutiu, Cristina Has

Certolizumab Pegol for the Treatment of Plaque Psoriasis in Routine Clinical Practice: One-Year Results from the CIMREAL Study

Bernhard Korge, Olivier Vanhooteghem, Charles W. Lynde, Alena Machovcova, Marc Perrussel, Elisavet Lazaridou, Claudio Marasca, David Vidal Sarro, Ines Duenas Pousa, Frederik Fierens, Paulette Williams, Saori Shimizu, Tanja Heidbrede, Richard B. Warren

Assessment of the Efficacy and Durability of IncobotulinumtoxinA in the Treatment of the Upper Face in Adult Women

Ada Trindade de Almeida, Carla de Sanctis Pecora, Elisa R. Marques, Leticia Contin, Camila Trindade de Almeida, Ana Lúcia da Cunha

Association Between Natural Hair Color, Race, and Alopecia

  • Open Access
  • Alopecia
  • Original Research

Kanika Kamal, David Xiang, Katherine Young, David E. Fisher, Arash Mostaghimi, Nicholas Theodosakis

Hair Shaft Abnormalities as a Dermoscopic Feature of Mycosis Fungoides: Pilot Results

Magdalena Jasińska, Joanna Czuwara, Nino Lortkipanidze, Agnieszka Michalczyk, Barbara Borkowska, Patrycja Gajda-Mróz, Marta Kurzeja, Małgorzata Olszewska, Lidia Rudnicka, Adriana Rakowska

Development of the Cutaneous Dermatomyositis Investigator Global Assessment (CDM-IGA): A De Novo IGA of Cutaneous Manifestations of Dermatomyositis

Stephanie McKee, Jason Xenakis, Harriet Makin, Chris Marshall, Randall Winnette, Rohit Aggarwal, Sarah L. Knight

Ruxolitinib Cream in Adolescents/Adults with Atopic Dermatitis Meeting Severity Thresholds for Systemic Therapy: Exploratory Analysis of Pooled Results from Two Phase 3 Studies

Eric L. Simpson, Leon Kircik, Andrew Blauvelt, Howard Kallender, Daniel Sturm, Mingyue Wang, Lawrence F. Eichenfield

Stable Response and Sustained Improvement of Itch and Sleep Symptoms in Patients with Atopic Dermatitis Treated with Lebrikizumab over 52 Weeks

Gil Yosipovitch, Peter Lio, Franz J. Legat, Raj Chovatiya, Mette Deleuran, Evangeline Pierce, Marta Casillas, Yuxin Ding, Fan E. Yang, Laia Bardolet, Sonja Ständer

The Impact of Lebrikizumab on Vaccine-Induced Immune Responses: Results from a Phase 3 Study in Adult Patients with Moderate-to-Severe Atopic Dermatitis

Jennifer Soung, Vivian Laquer, Joseph F. Merola, Angela Moore, Hany Elmaraghy, Chaoran Hu, Maria Lucia Buziqui Piruzeli, Evangeline Pierce, Esther Garcia Gil, Abel D. Jarell

Bridging the Gap: Comparing Patient-Clinician Views on Treatment Goals and Communication in the Management of Atopic Dermatitis Within the Asia–Pacific Region

Chia-Yu Chu, Yung Chan, Siriwan Wananukul, Hao Cheng, Nisha Suyien Chandran, Ramesh Bhat, Sang Wook Son, Han-Fang Liao, Sean Gardiner, See-Hwee Yeo, Sophie Bozhi Chen, Qi Qing Ng, Yoko Kataoka

Dupilumab in Patients with Atopic Dermatitis: A Multicentric, Long-Term, Real-World Portuguese Study

Tiago Torres, Maria João Cruz, Margarida Gonçalo, Paulo Filipe, Bruno Duarte, João Alves, José Miguel Alvarenga, Gilberto Rosa, Duarte Flor, José Ramos, Diogo Sousa, Aureliu Rosca, César Magalhães, Cristina Claro, Joana Rocha, Catarina Vilarinho, Fernando Mota, Alberto Mota, Maria João Paiva Lopes

Psychometric Evaluation of the Facial and Total Vitiligo Area Scoring Index Instruments in the TRuE-V Phase 3 Studies

  • Open Access
  • Vitiligo
  • Original Research

Kristen Bibeau, Kathleen Butler, Mingyue Wang, Konstantina Skaltsa, Iltefat H. Hamzavi

Deucravacitinib Improves Patient-Reported Outcomes in Patients with Moderate to Severe Psoriasis: Results from the Phase 3 Randomized POETYK PSO-1 and PSO-2 Trials

April W. Armstrong, Matthias Augustin, Jennifer L. Beaumont, Tan P. Pham, Stacie Hudgens, Kenneth B. Gordon, Joe Zhuo, Brandon Becker, Yichen Zhong, Renata M. Kisa, Subhashis Banerjee, Kim A. Papp

Patients with Moderate-to-Severe Atopic Dermatitis Maintain Stable Response with No or Minimal Fluctuations with 1 Year of Lebrikizumab Treatment

Jonathan I. Silverberg, Andreas Wollenberg, Linda Stein Gold, James Del Rosso, Gil Yosipovitch, Peter Lio, Jose-Manuel Carrascosa, Gaia Gallo, Yuxin Ding, Zhenhui Xu, Marta Casillas, Evangeline Pierce, Helena Agell, Sonja Ständer

Clinical Characteristics and Disease Burden of Patients with Moderate-to-Severe Generalized Pustular Psoriasis Flares in Taiwan

Chun-Wei Lu, Chien-Yu Tseng, Chuang-Wei Wang, Shang-Hung Lin, Chun-Bing Chen, Rosaline Chung-Yee Hui, Ching-Chi Chi, Yu-Huei Huang, Chih-Hung Lee, Fang-Ju Lin, Wen-Hung Chung

Psoriasis and Sleep Disturbance: A US Population-Based Study Using the NHANES Database

Payton Smith, Joy Q. Jin, Riley K. Spencer, Kareem G. Elhage, Chandler E. Johnson, Kathryn Haran, Allison Kranyak, Mitchell S. Davis, Marwa Hakimi, Aric A. Prather, Katie L. Stone, Wilson Liao, Tina Bhutani

Practical Management of the JAK1 Inhibitor Abrocitinib for Atopic Dermatitis in Clinical Practice: Special Safety Considerations

Melinda J. Gooderham, Marjolein de Bruin-Weller, Stephan Weidinger, Michael J. Cork, Lawrence F. Eichenfield, Eric L. Simpson, Athanasios Tsianakas, Urs Kerkmann, Claire Feeney, William Romero

Correction: Ixekizumab Demonstrates Rapid and Consistent Efficacy for Patients with Psoriatic Arthritis, Regardless of Psoriasis Severity

April W. Armstrong, Tarannum Jaleel, Joseph F. Merola, Alice B. Gottlieb, Saakshi Khattri, Cameron C. Helt, William N. Malatestinic, Sarah E. Ross, Marcus E. Ngantcha, Kurt de Vlam

Innovations in AML: insights and practical guidance

Hear directly from acute myeloid leukemia experts in this vodcast series focussing on innovations in molecular testing, emerging therapies, and targeted treatments, and get practical advice for improving the care of your patients with relapsed or refractory disease.

Supported by:
  • Rigel Pharmaceuticals, Inc.
Developed by: Springer Health+ IME
Learn more

ADA 2025

Unlock your free and exclusive access to the latest news from the American Diabetes Association’s 85th Scientific Sessions.

Read more